Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces SAR566658 Clinical Findings


Sunday, 20 Oct 2013 12:30pm EDT 

ImmunoGen Inc announced the presentation of interim data from the ongoing Phase I trial of Sanofi's SAR566658 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting (abstract #A73) being held in Boston. SAR566658 is an ADC targeted to CA6, which is found on many cases of ovarian, breast, and other epithelial cancers. The data reported support that SAR566658 is generally well tolerated and can induce objective responses and sustained stable disease in heavily pretreated patients with CA6-positive cancers. A total of 34 patients received SAR566658 at doses ranging from 10-240 mg/m2 (6.5 mg/kg), administered every three weeks. Overall, SAR566658 was well tolerated, with limited adverse events typically associated with cytotoxic chemotherapy (hematologic toxicity, peripheral neuropathy). Reversible ocular corneal changes were seen at the higher doses. The recommended dose for further evaluation was determined to be 190 mg/m2, and SAR566658 is now being assessed at that dose in the extension phase of the trial. 

Company Quote

11.52
0.03 +0.26%
22 Aug 2014